6 Analysts Have This to Say About Karyopharm Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 6 analysts have published their opinion on Karyopharm Therapeutics (NASDAQ:KPTI) stock. The average price target for KPTI has increased by 12.44% from the previous average price target of $6.67 to $7.5. The majority of the analysts are bullish on the stock.
August 04, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts are mostly bullish on Karyopharm Therapeutics (NASDAQ:KPTI) with an increased average price target of $7.5, up by 12.44% from the previous target.
The majority of the analysts are bullish on KPTI, indicating a positive sentiment towards the stock. The increase in the average price target suggests that they expect the stock price to rise in the future. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100